Same Indication

Ixekizumab vs Nivolumab

Ixekizumab vs Nivolumab: Overview

This comparison examines the pharmacological differences between Ixekizumab and Nivolumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days.

Chemical Properties

Type: Ixekizumab β€” Antibody; Nivolumab β€” Antibody.